Seeking Alpha
10 Nov 2026, 10:41 UTC · 1w ago
TransMedics: Growth Is Accelerating Again And 2027 Looks Promising
Impact · against what's priced in
The news is largely neutral as the market had already priced in a revenue growth glide path of 22-25%. While the raised guidance and service growth are positive, they align with the current valuation's assumptions regarding growth deceleration and logistics scaling.
- TMDX+0.00
Already priced in
- The price assumes
Revenue growth decelerating from over 37% to the 22-25% annual guidance range
The projected organic growth of 24-26% is almost identical to the deceleration range the market has already baked into the current price.
What TMDX's price assumes · Sep 24





